Bivalirudin
is a thrombin –inhibiting oligopeptide that was developed through rational drug
as a hirudin analogue. It is a thrombin inhibitor consisting of 20 –amino
acid structure combining a carboxy-terminal region that recognizes thrombin’s
fibrin (ogen)- binding sate. It works by blocking of the formation
of blood clots. Likewise, desmopressin is an antidiuretic harmone. It works by
causing the kidneys to produce less urine. Bivalirudin is used as an
anticoagulant in the patients with unstable angina who are undergoing
percutaneous transluminal coronary angioplasty (PTCA) and in patients undergoing
percutaneous coronary intervention (PCI). Moreover, Bivalirudin is used in
conjuction with other medicines. Further, desmopressin is used to manage
temporarily increased thirst and urination caused by head injury.
Market Size and Forecast
The market
is expected to increase significantly over the forecast period 2017-2024. The
bivalirudin is facing increased demand due to its application in the treatment
of coronary artery disease and cancer. Likewise, the demand for
desmopressin is increasing due to its use in bedtime wetting and nocturia.
Market Segmentation:
Our in
depth analysis of the bivalirudin and desmopressin market includes the
following segments:
By Use:
Percutaneous
Transluminal Coronary Angioplasty (PTCA) Procedures
Percutaneous
Coronary Intervention (PCI) Procedures
Others
The global
bivalirudin and desmopressin market is further classified on the basis of
region as follows:
By Region:
North
America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity
Analysis
Latin
America (Brazil, Mexico, Rest of Latin America) Market size, Y-O-Y growth &
Opportunity Analysis
Western
and Eastern Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium,
Netherlands & Luxembourg, Rest of Western Europe) Market size, Y-O-Y growth
& Opportunity Analysis
Asia-Pacific
(China, India, Japan, Singapore, Australia, New Zealand, Rest of Asia) Market
size, Y-O-Y growth & Opportunity Analysis.
Growth Drivers and Challenges
The market
growth is driven by the rise in the number of the cases of cardiovascular
diseases. According to the American Heart Association, the number of the adults
living with the heart failure has increased from 5.7 million (2009-12) to about
6.5 million (2011-2014). Further, the cardiovascular diseases are on rise thereby
leading to the increased number of deaths across the world. The cardiovascular
diseases include coronary artery disease, high blood pressure and stroke. The
patients with ST-elevation myocardial infarction (STEMI) is often achieved via
primary percutaneous coronary intervention (PCI), thus reducing major adverse
cardiovascular diseases. Adjunctive antithrombotic and antiplatelet therapies
are used during PCI to reduce MACE rates. The most commonly used agents include
low unfractioned heparin. These agents reduce the rates of peri-procedural
ischemic and thrombotic events, but these agents produce complications in the
form of increased bleeding, but bivalirudin has emerged as a safe alternative
to heparin and helps in reducing the risk of coronary artery disease. Moreover,
bivalirudin has advantages over the heparin including reduced rates of
mortality, cardiovascular mortality and major bleeding events. Therefore, this
has led to the adoption of bivalirudin as a drug for the treatment of coronary
artery disease, thus leading to the expansion of the bivalirudin market.
The increase in the number of cancer patients is another reason that is
driving the growth of bivalirudin
market. According to the World Health Organization (WHO), approximately 14
million cases came into the light in 2012. Moreover, the cancer is second
leading cause of the death globally, and was responsible for 8.8 million deaths
in 2015. The expansion of the desmopressin market is driven by the increasing
number of nocturia cases among elderly men and women. Nocturia is a lower
urinary tract symptom which involves the need for passing urine at night,
resulting in the disturbance of sleep. As a result, it frequently impacts upon
the quality of life (QoL) and wellbeing of individuals. The prevalence
increases with the age and has reported to be as high as 77% and 94% in elderly
women and men respectively, thus leading to the expansion of the desmopressin
market. Desmopressin works as an effective treatment for patients with
nocturia. The antidiuretic effect of desmopressin decreases the number of the
night voids and prolongation of the sleep period as compared to placebo.
However, the market growth of Bivalirudin is hindered by various reasons
including the cost and the reluctance to change from existing anti-thrombotic
agents used.
Key Players
Pfizer,
Inc. (US)
Company
Overview
Key
Product Offerings
Business
Strategy
SWOT
Analysis
Financials
Bayer
Healthcare AG (Germany)
GlaxoSmithKline
PLC. (UK)
Abott
India Limited (India)
Mitsubishi
Tanabe Pharma Corporation (Japan)
Sun
Pharmaceuticals Industries Limited
Ferring
Pharmaceuticals
Eisai Inc.
Boehringer
Ingelheim
Sanofi
S.A.
Scope and
Context
Overview
of the Parent Market
Analyst
View
Segmentation
The Global
Bivalirudin and Desmopressin Market is segmented as follows:
By Use
Market Size & Y-O-Y Growth Analysis
By Region
Market Size & Y-O-Y Growth Analysis
Market
Dynamics
Supply
& Demand Risk
Competitive
Landscape
Porter’s
Five Force Model
Geographical
Economic Activity
Key
Players (respective SWOT Analysis) and their Strategies and Product Portfolio
Recent
Trends and Developments
Industry
Growth Drivers and Challenges
Key
Information for Players to establish themselves in current dynamic environment
To know
more about this research, kindly visit:
For Table of Content &
Free Sample Report Contact:
Ajay
Daniel
Email:
ajay.daniel@researchnester.com
U.S. +1 646 586 9123
U.K. +44 203 608 5919
No comments:
Post a Comment